This company has been marked as potentially delisted and may not be actively trading. NASDAQ:INNT Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Innovate Biopharmaceuticals Stock (NASDAQ:INNT) Get INNT alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.56▼$1.4252-Week Range N/AVolumeN/AAverage Volume525,982 shsMarket Capitalization$21 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina. Read More Receive INNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INNT Stock News HeadlinesMajor breakthrough of Sanyou Biopharmaceuticals AI-STALMay 20, 2026 | finance.yahoo.comBiopharmaceutical Industry Set for Unprecedented Growth in 2025: Key Trends and Contributions by Global LeadersFebruary 4, 2026 | finance.yahoo.comEveryone's chasing SPCX at $160. Don't.The SpaceX IPO opened at $150 and retail investors chased it past $160 - that's 266 times earnings for the most expensive IPO in history. Institutions who got in at an $800 billion valuation now have someone to sell to. There's one small, publicly traded company that builds the infrastructure Musk cannot operate without. You don't need an IPO allocation to get exposure to this $2 trillion story. Dylan Jovine is giving away the ticker name for free.June 20 at 1:00 AM | Behind the Markets (Ad)1Elevan Biopharmaceuticals, Inc. Announces the Development of Its Next-Generation Peptide Therapeutics Headquarters in Fishers, IndianaJune 17, 2025 | finance.yahoo.comVascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell DiseaseJune 12, 2025 | tmcnet.comTagomics awarded £860 k Innovate UK Biomedical Catalyst grant for detection of colorectal cancerJune 10, 2025 | msn.comContext Therapeutics Names Dr. Karen Smith as Interim Chief Medical OfficerMay 10, 2025 | msn.comInnovent Biologics: Innovent Announces 2024 Annual Results and Business UpdatesMarch 26, 2025 | finanznachrichten.deSee More Headlines INNT Stock Analysis - Frequently Asked Questions How were Innovate Biopharmaceuticals' earnings last quarter? Innovate Biopharmaceuticals Inc (NASDAQ:INNT) announced its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.11). What other stocks do shareholders of Innovate Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innovate Biopharmaceuticals investors own include 9 Meters Biopharma (NMTR), NIO (NIO), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET), Iterum Therapeutics (ITRM), Meta Platforms (META) and Micron Technology (MU). Company Calendar Last Earnings3/18/2019Today6/20/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:INNT CIK1551986 Webwww.innovatebiopharma.com Phone919-275-1933FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.05 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-234.42% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / BookN/AMiscellaneous Outstanding Shares41,325,000Free FloatN/AMarket Cap$21 thousand OptionableNot Optionable Beta-0.39 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:INNT) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersRead this before you touch SPCXSPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...Altimetry | SponsoredForget the million-dollar nest eggNearly 2 in 3 Americans fear running out of money more than death - and chasing a $1.5 million nest egg isn't ...Investors Alley | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]George Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovate Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
